HomeCompareMDSQF vs PFE

MDSQF vs PFE: Dividend Comparison 2026

MDSQF yields 458.61% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MDSQF wins by $31684.27M in total portfolio value
10 years
MDSQF
MDSQF
● Live price
458.61%
Share price
$0.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31684.32M
Annual income
$22,173,346,914.44
Full MDSQF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MDSQF vs PFE

📍 MDSQF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDSQFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDSQF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDSQF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDSQF
Annual income on $10K today (after 15% tax)
$38,981.88/yr
After 10yr DRIP, annual income (after tax)
$18,847,344,877.27/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MDSQF beats the other by $18,847,322,557.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDSQF + PFE for your $10,000?

MDSQF: 50%PFE: 50%
100% PFE50/50100% MDSQF
Portfolio after 10yr
$15842.19M
Annual income
$11,086,686,586.58/yr
Blended yield
69.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MDSQF
No analyst data
Altman Z
257.2
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDSQF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDSQFPFE
Forward yield458.61%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$31684.32M$49.6K
Annual income after 10y$22,173,346,914.44$26,258.71
Total dividends collected$30840.02M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MDSQF vs PFE ($10,000, DRIP)

YearMDSQF PortfolioMDSQF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$56,561$45,861.04$9,153$693.39+$47.4KMDSQF
2$302,945$242,425.07$8,593$849.25+$294.4KMDSQF
3$1,537,654$1,213,502.54$8,336$1,066.78+$1.53MMDSQF
4$7,401,693$5,756,403.47$8,437$1,384.80+$7.39MMDSQF
5$33,816,241$25,896,429.35$9,013$1,875.40+$33.81MMDSQF
6$146,756,699$110,573,321.01$10,306$2,680.72+$146.75MMDSQF
7$605,505,638$448,475,970.02$12,820$4,101.38+$605.49MMDSQF
8$2,377,212,197$1,729,321,164.11$17,673$6,826.70+$2377.19MMDSQF
9$8,888,763,311$6,345,146,260.33$27,543$12,591.86+$8888.74MMDSQF
10$31,684,323,657$22,173,346,914.44$49,560$26,258.71+$31684.27MMDSQF

MDSQF vs PFE: Complete Analysis 2026

MDSQFStock

Minsud Resources Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Argentina. The company explores for copper, molybdenum, silver, and gold deposits. Its principal project is the Chita Valley project that consists of the Chita, Brechas Vacas, and Minas de Pinto mineral concessions, as well as five additional adjacent properties covering an area of approximately 19,883 hectares located in the province of San Juan, Argentina. The company also holds a 100% interest in La Rosita project, which consists of the Alfa II mine and Alfa III mining concessions covering an area of 5,986 hectares located in the low sulfidation epithermal metallogenic province of the Deseado Massif, Patagonia, Argentina. The company was formerly known as Rattlesnake Ventures Inc. and changed its name to Minsud Resources Corp. in May 2011. Minsud Resources Corp. was founded in 2003 and is headquartered in Toronto, Canada.

Full MDSQF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MDSQF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDSQF vs SCHDMDSQF vs JEPIMDSQF vs OMDSQF vs KOMDSQF vs MAINMDSQF vs JNJMDSQF vs MRKMDSQF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.